WCO-IOF: Changes with QCT, DXA, and TBS between denosumab, alendronate, & placebo
Changes in lumbar spine QCT, DXA, and TBS following treatment with denosumab (DMAB), alendronate (ALN), or placebo (PBO) in postmenopausal women with low bone mass
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
215 postmenopausal women with low spine or total hip bone mineral density (BMD) were randomized to treatment with either denosumab, alendronate, or placebo for a period of 12 months. Quantitative computed tomography (QCT) and densitometry (DXA), in addition to a novel trabecular bone score (TBS) were evaluated to determine if a differences exists between the information provided by these three mea...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE